Accelerate Diagnostics, Inc. (AXDX)
NASDAQ: AXDX · Real-Time Price · USD
1.700
-0.050 (-2.86%)
Nov 20, 2024, 4:00 PM EST - Market closed
Accelerate Diagnostics Revenue
Accelerate Diagnostics had revenue of $2.98M in the quarter ending September 30, 2024, a decrease of -9.82%. This brings the company's revenue in the last twelve months to $11.91M, down -0.79% year-over-year. In the year 2023, Accelerate Diagnostics had annual revenue of $12.06M, down -5.43%.
Revenue (ttm)
$11.91M
Revenue Growth
-0.79%
P/S Ratio
2.95
Revenue / Employee
$88,873
Employees
134
Market Cap
40.25M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 12.06M | -693.00K | -5.43% |
Dec 31, 2022 | 12.75M | 970.00K | 8.23% |
Dec 31, 2021 | 11.78M | 617.00K | 5.53% |
Dec 31, 2020 | 11.17M | 1.87M | 20.09% |
Dec 31, 2019 | 9.30M | 3.63M | 63.97% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
NeueHealth | 996.89M |
Fortress Biotech | 81.50M |
Omega Therapeutics | 8.10M |
LAVA Therapeutics | 7.40M |
Nexalin Technology | 162.08K |
Daxor | 154.21K |
AXDX News
- 12 days ago - Accelerate Diagnostics, Inc. (AXDX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Accelerate Diagnostics Reports Third Quarter 2024 Financial Results - PRNewsWire
- 26 days ago - Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results - PRNewsWire
- 7 weeks ago - Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System - PRNewsWire
- 3 months ago - Accelerate Diagnostics, Inc. (AXDX) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Accelerate Diagnostics Reports Second Quarter 2024 Financial Results - PRNewsWire
- 3 months ago - Accelerate Diagnostics Announces a Successful Completion of its WAVE™ Pre-Clinical Trial - PRNewsWire
- 3 months ago - Accelerate Diagnostics Scheduled Call to Review 2024 Second Quarter Results - PRNewsWire